Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03475251
Other study ID # CS1003-101
Secondary ID ACTRN12618000382
Status Completed
Phase Phase 1
First received
Last updated
Start date May 9, 2018
Est. completion date May 31, 2021

Study information

Verified date February 2022
Source CStone Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date May 31, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor and have progressed, are intolerant to, refuse to accept or do not have access to standard therapy. 2. ECOG performance status of 0 or 1. 3. Subjects with evaluable but non-measurable lesion are eligible for Phase Ia. Subjects must have at least one measurable lesion per RECIST Version 1.1 to be eligible for Phase Ib. 4. Archived tumor tissue samples need to be collected, or subjects consent to undergo pre-treatment biopsy if archived sample is not available. 5. Life expectancy = 3 months. 6. Subject must have adequate organ function. 7. Use of effective contraception (males and females). Exclusion Criteria: 1. Subjects with known symptomatic or untreated brain metastasis or other CNS metastasis. 2. Subjects with active autoimmune diseases or history of autoimmune diseases. 3. Subjects who have to receive glucocorticoids (prednisone at > 10 mg/day or equivalent) or other immunosuppression within 14 days prior to the first dose of CS1003. 4. Subjects with other malignant tumor(s) in the past 2 years are not eligible for Phase Ib, except for those with basal cell carcinoma, in situ breast cancer and cervical carcinoma in situ who have undergone radical treatment. 5. Subjects who have received any immune checkpoint treatment, including PD-1, PD-L1, etc. 6. Receipt of chemotherapy, targeted therapy, or any other anti-cancer systemic treatment within 2 weeks prior to the first dose of CS1003. 7. Receipt of major surgical procedure or wide field of radiation within 28 days prior to the first dose of CS1003, local radiotherapy within 14 days prior to the first dose of CS1003, or radioactive agents within 56 days before the first dose of CS1003. 8. Receipt of Chinese herbal medicine or Chinese prepared medicine within 7 days prior to the first dose of CS1003. 9. Receipt of live vaccine within 28 days prior to the first dose of CS1003. 10. History of interstitial lung disease or non-infectious pneumonitis, except for those induced by radiation therapies. 11. History of HIV infection. 12. Subjects with active Hepatitis B and C infection (HBV DNA = 1000 cps/mL or 200 IU/mL) requiring therapy. 13. Subjects with active infection of tuberculosis. 14. Subjects with signs or symptoms of any active infection requiring systemic therapy. 15. History of organ transplantation. 16. Unresolved toxicities from prior anti-cancer therapy. 17. History of any irAE of Grade = 3. 18. History of uncontrolled allergic asthma and serious hypersensitive reaction to monoclonal antibodies. 19. History of alcoholism or drugs abuse. 20. Subjects with major cardiovascular diseases. 21. Any condition that, in the opinion of the investigator or sponsor, would jeopardize compliance. For more information regarding trial participation, please contact at cstonera@cstonepharma.com

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CS1003
In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
CS1003
CS1003 to be intravenously administered at the dose level determined during the dose escalation part
Drug:
Regorafenib
Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle

Locations

Country Name City State
Australia Scientia Clinical Research Ltd Randwick New South Wales

Sponsors (1)

Lead Sponsor Collaborator
CStone Pharmaceuticals

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events From the day of first dose to 30 days after last dose of CS1003
Secondary Area under the plasma concentration-time curve (AUC) From the day of first dose to 30 days after last dose of CS1003
Secondary Maximum plasma concentration (Cmax) From the day of first dose to 30 days after last dose of CS1003
Secondary Time to reach maximum plasma concentration (Tmax) From the day of first dose to 30 days after last dose of CS1003
Secondary Terminal elimination half-life (t1/2) From the day of first dose to 30 days after last dose of CS1003
Secondary Disease assessment by CT/MRI scan To be performed every 9 weeks during treatment period (up to 2 years) and within 30 days after last dose of CS1003
Secondary Anti-CS1003 antibody From the day of first dose to 30 days after last dose of CS1003
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1